Interferon Beta-1a Injection for MS from Canada
A recombinant interferon beta-1a formulation for relapsing multiple sclerosis treatment, regulating immune processes. Falls under HTS 3002.90.52.50 as an immunological product (interferon) prepared for therapeutic use via biotechnological methods. It reduces disease activity in neurological conditions.
Duty Rate — Canada → United States
0%
Rate breakdown
9903.03.030%Articles the product of any country, as provided for in subdivision (aa)(ii) of U.S. note 2 to this subchapter
Import Tips
• Include recombinant DNA origin docs and bioequivalence studies for biologics approval
• Use validated cold chain with temperature excursions monitored for protein integrity
• Specify therapeutic dosing to distinguish from research cytokines